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ABSTRACT
Glioblastoma is the most aggressive brain tumor in adults with a median 
survival below 12 months in population-based studies. The main reason for tumor 
recurrence and progression is constitutive or acquired resistance to the standard 
of care of surgical resection followed by radiotherapy with concomitant and 
adjuvant temozolomide (TMZ/RT→TMZ). Here, we investigated the role of microRNA 
(miRNA) alterations as mediators of alkylator resistance in glioblastoma cells. Using 
microarray-based miRNA expression profiling of parental and TMZ-resistant cultures 
of three human glioma cell lines, we identified a set of differentially expressed miRNA 
candidates. From these, we selected miR-138 for further functional analyses as this 
miRNA was not only upregulated in TMZ-resistant versus parental cells, but also 
showed increased expression in vivo in recurrent glioblastoma tissue samples after 
TMZ/RT→TMZ treatment. Transient transfection of miR-138 mimics in glioma cells 
with low basal miR-138 expression increased glioma cell proliferation. Moreover, miR-
138 overexpression increased TMZ resistance in long-term glioblastoma cell lines and 
glioma initiating cell cultures. The apoptosis regulator BIM was identified as a direct 
target of miR-138, and its silencing mediated the induced TMZ resistance phenotype. 
Altered sensitivity to apoptosis played only a minor role in this resistance mechanism. 
Instead, we identified the induction of autophagy to be regulated downstream of the 
miR-138/BIM axis and to promote cell survival following TMZ exposure. Our data 
thus define miR-138 as a glioblastoma cell survival-promoting miRNA associated with 
resistance to TMZ therapy in vitro and with tumor progression in vivo.
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INTRODUCTION
Glioblastomas are the most aggressive primary brain 
tumors associated with a rapid and invariably fatal clinical 
course [1]. The current standard of care includes surgical 
resection followed by radiotherapy with concomitant 
and adjuvant chemotherapy with the alkylating agent 
temozolomide (TMZ/RT→TMZ) [2, 3]. Although TMZ 
prolongs progression-free and overall survival in 
glioblastoma patients, recurrence is inevitable because of 
infiltrative growth and inherent resistance to genotoxic 
stress. Even glioblastomas with favorable molecular profiles 
characterized by isocitrate dehydrogenase 1 or 2 mutation 
or O6-methylguanine DNA methyltransferase (MGMT) 
promoter methylation are prone to fail therapy.
MicroRNAs (miRNAs) are short, non-coding, 
single-stranded RNA molecules that function as negative 
post-transcriptional regulators of gene expression by 
binding to the 3′-untranslated region (3′UTR) of target 
mRNA, causing its cleavage or translational repression 
[4]. MiRNAs thereby regulate important cellular features 
such as growth, survival and death. Their expression is 
often deregulated in pathological conditions including 
cancer, where aberrant miRNA expression contributes to 
proliferation, invasion and resistance to apoptosis [5–7]. 
MiRNAs associated with TMZ resistance in glioblastoma 
include miR-195 [8], miR-9 [9], miR-125b [10], miR-136 
[11], miR-181b [12], and miR-221/222 [13].
We have established a model of acquired 
resistance to TMZ in three well-characterized long-term 
glioblastoma cell lines (LTC) and investigated several 
candidate pathways of resistance to TMZ [14]. Here, we 
report a microarray-based screen for differential miRNA 
expression in pairs of parental and TMZ-resistant cultures. 
We identified a set of differentially expressed miRNA 
candidates and selected miR-138 for further analysis. 
miR- 138 has been implicated in the pathogenesis of 
several cancers [15–17], including gliomas [18, 19], 
however, it has not been related to therapy resistance. 
Here, we demonstrate that miR-138 may mediate TMZ 
resistance by targeting Bcl-2-like protein 11 (BCL2L11), 
also known as BIM, a BH3-only apoptosis initiator from 
the Bcl-2 protein family [20]. 
RESULTS
miR-138 is upregulated in glioma cells with 
acquired TMZ resistance and in recurrent 
glioblastomas in vivo
Microarray-based miRNA expression profiling of 
parental and TMZ-resistant (TMZR) LN-18, LN-229 and 
LN-308 cells revealed several differentially expressed 
MiRNAs (Figure 1A), including several miRNAs 
previously implicated in TMZ resistance, such as mir-125b 
[10], miR- 181 [12] or miR-221/222 [13]. We focused on 
MiRNAs upregulated in LN-308 cells since the mechanism 
of TMZ resistance in this cell line remained unclear [14]. 
We selected miR-138 for further investigations which 
showed increased expression in LN-18-resistant (LN-18_R) 
and LN-308-resistant (LN-308_R) cells (Figure 1B), and 
confirmed upregulation in these cells versus parental cells 
by real-time qPCR (Figure 1C). Next, we screened the 
baseline expression of miR-138 in a panel of 9 LTC and 5 
GIC (glioma-initiating cells) lines (Figure 1D). There was 
no significant correlation of baseline miR-138 expression 
with sensitivity to TMZ in clonogenic survival assays 
either for all cell lines pooled (r = 0.25, p = 0.39) (Figure 
S1A), LTC alone (r = 0.03, p = 0.95) (Figure S1B), or GIC 
alone (r = 0.3. p = 0.68) (Figure S1C). We confirmed that 
the expression of miR-138 was increased in 9 of 10 paired 
tissues from primary and recurrent glioblastomas following 
TMZ/RT→TMZ, corroborating the potential significance 
of this miRNA in human glioblastoma in vivo (Figure 1E).
miR-138 overexpression increases glioma cell 
proliferation
Next we assessed the effects of miR-138 
overexpression in LN-308 and LN-319 cells selected for their 
low baseline expression of miR-138 (Figure 1D, Figure 2A). 
miR-138 induced proliferation of LN-308 glioma cells 
as indicated by BrdU incorporation assay (Figure 2B), 
confirmed by trypan blue dye exclusion assays over time 
in both cell lines (Figure 2C). Cell cycle analysis by flow 
cytometry showed a reduced G2/M fraction in the miR-138 
overexpressing cells at day 6 post transfection (Figure 2D). 
Overexpression of miR-138 induces resistance to 
TMZ and CCNU in glioma cells
In LN-308 and ZH-305 cells, chosen for their low 
baseline expression of miR-138, overexpression of miR-138 
conferred protection from TMZ. The EC50 shifted from 
40 to 120 μM in LN-308 and from 8 to 16 μM in ZH-305 
(Figure 3A). In contrast, no such effect was seen in LN-18 
or LN-428 cells (Figure S2A), which have higher baseline 
expression of miR-138 (Figure 1D). When miR-138-
overexpressing LN-308 and ZH-305 cells were exposed 
to increasing concentrations of another alkylating agent, 
CCNU, a gain of resistance was also achieved (Figure 3B). 
No cross-resistance was observed to irradiation, to the 
topoisomerase II inhibitor etoposide, or to the vinca alkaloid 
vincristine (Figure S2B). To address whether the TMZ resistant 
phenotype is reversed by downregulation of endogeneous 
miR-138, we transiently transfected miR-138-expressing 
LN-18 and LN-229 cells with a specific miR- 138 inhibitor 
or a non-targeting negative control molecule. Transfection 
efficacy was assessed by real-time qPCR (Figure S3A) 
and by fluorescent light microscopy (Figure S3B). 
Immunoblot analysis for expression of the miR-138 target 
SOX4 [17] in LN-229 cells confirmed the biological 
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activity of miR-138 inhibition (Figure S3C). Conversely, 
the overexpression of miR-138 decreased SOX4 levels by 
40% in LN-308 cells selected for their low baseline miR-138 
expression. However, the inhibitor did not increase sensitivity 
to TMZ in LN-18, LN-18_R, LN-229 or LN- 229_R cells 
(Figure S3D). We assume that upon miR- 138 inhibitor 
application, residual endogenous levels of miR-138 are still 
high enough to preserve the primary resistant phenotype.
Predicted miR-138 targets in mediating TMZ 
sensitivity – no role for activated leukocyte cell 
adhesion molecule (ALCAM)
ALCAM, an in silico predicted target of miR- 138 
[21], emerged as a candidate decreased in LN-18_R 
and LN-229_R cells from the microarray-based mRNA 
expression profiling (data not shown). According to The 
Figure 1: mir-138 is significantly upregulated in TMZ-resistant glioma cell lines and in recurrent glioblastoma. (A) Heat-
map of differentially expressed miRNA obtained by microarray-based expression profiling of parental (P) and TMZ-resistant (R) LN-18, 
LN-229 and LN-308 cells using GeneChip® miRNA 2.0 arrays. Results were obtained from hybridization of three independent batches of 
each P and R cell line. Rows and columns were clustered hierarchically using the hclust method of R. The expression profile distances were 
calculated based on the Pearson correlation coefficients between miRNAs and samples. (B) Box plots showing upregulation of miR- 138 
expression in resistant versus parental cell lines of LN-18 and LN-308 but not LN-229 based on microarray data. (C) Real-time qPCR 
analysis for miR-138 expression in the paired P and R cells (n = 3, unpaired Student’s t-test). (D) Relative baseline expression levels of 
miR-138 in LTC (gray columns) and GIC (striped columns) assessed by real-time qPCR (n = 3). (E) Real-time qPCR analysis of miR- 138 
expression in paired primary and recurrent glioblastoma tissues of 10 patients using U6 snRNA as reference (*p < 0.05; **p < 0.01; 
***p < 0.001; paired Student´s t-test).
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Cancer Genome Atlas (TCGA) online dataset [22], low 
expression levels of ALCAM correlate with shorter overall 
survival of glioblastoma patients (n = 504; average cut-
off = 590.3; p = 5.2e−03) (Figure S4A). We confirmed 
a downregulation at protein level by immunoblot in 
LN-18_R and LN-229_R cells (Figure S4B). However, 
siRNA-mediated gene silencing of ALCAM (Figure S4C) 
did not confer TMZ resistance (Figure S4D), which 
indicates that ALCAM downregulation alone is not 
sufficient to mediate TMZ resistance in glioma cells.
BIM is a direct target of miR-138 and modulates 
TMZ resistance
We further investigated additional predicted 
miR- 138 targets focusing on those that were found to be 
downregulated at the mRNA level by Affymetrix gene 
chip analyses of the three parental and resistant glioma cell 
lines. The predicted target BCL2L11 (or BIM) was found 
to be downregulated in all three resistant cell lines in the 
Affymetrix array. Accordingly, in the TCGA online dataset, 
low expression levels of BCL2L11/BIM correlate with 
shorter overall survival of glioblastoma patients (Figure S5). 
Down-regulation of BIM protein was confirmed by 
immunoblot analysis in LN-229_R and LN-308_R cells 
(Figure 4A). BIM has three predominant isoforms generated 
by alternative splicing, BIMEL (extra-large), BIML (large) and 
BIMs (small). These isoforms are ubiquitously expressed 
with a tissue-specific variation, where BIMEL is the most 
abundant isoform. Only BIMEL was detected in our glioma 
cells. This case of preferential expression of one BIM 
isoform in different cell types/tissues has been previously 
described [23, 24]. BIM levels were reduced or increased, 
respectively, in glioma cells transfected with miR-138 
mimic or miR-138 inhibitor (Figure 4B). Luciferase reporter 
assays assessing miR-138 binding to the BIM- 3′UTR region 
Figure 2: miR-138 induces proliferation of glioma cells in vitro. (A) Transfection efficiency of mimic-138 in LN-18, LN-308, 
LN-319, LN-428 and ZH-305 cells was assessed by real-time qPCR of mimic and control transfected cells (n = 3). The final concentration 
of mimic/control was 50 nM in LTC and 100 nM in GIC. (B) BrdU incorporation assay was performed in LN-308 cells transfected with 
mimic-138 or control (50 nM) (***p < 0.001, unpaired Student’s t-test). (C) LN-308 (left panel) or LN-319 (right panel) cells were 
transfected with mimic-138/control (50 nM) and proliferation and cell death were measured by counting trypan blue stained cells at days 1, 
3, 5 and 7 after reseeding the transfected cells. Assay was analyzed by unpaired Student’s t-test. (D) Flow cytometric cell cycle analysis of 
mimic-138/control (50 nM) transfected LN-308 cells was performed by PI staining at day 3 and 6 post-transfection.
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confirmed BIM as a direct target of miR-138. Additionally, 
control vectors carrying either each at a time or both 
mutated miR-138-binding sites in the BIM-3′UTR region 
revealed that the binding site 1223-1249 nt is more potently 
regulated by miR-138 (Figure 4C; Figure S6A). SiRNA-
mediated BIM gene silencing (Figure 4D, Figure S6B) 
increased TMZ resistance in LN-308 cells (Figure 4E). 
To confirm the role of the BIM-related apoptotic pathway, 
we employed sub-lethal concentrations of ABT-737 
(Figure S6C), a small-molecule BH3 mimetic that directly 
inhibits anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w 
[25]. The resistant phenotype induced by BIM gene 
silencing was indeed reversed by ABT-737 (Figure 4F).
TMZ treatment does not induce acute apoptosis, 
but modulates expression of Bcl-2 family 
proteins
BIM belongs to the BH-3 only group of pro-
apoptotic Bcl-2 family members and is a direct regulator 
of the intrinsic cell death pathway. To assess whether TMZ 
protection of glioma cells by miR-138 over-expression or by 
BIM silencing involves cell death regulation, we performed 
flow cytometry cell death analysis by Annexin V/PI staining 
at days 1 and 3 after TMZ treatment. The overall amount 
of cell death induced by TMZ was low (up to 10% on day 
3). Still, miR-138 mimic or siBim -transfected cells showed 
reduced cell death upon TMZ stimulation at day 3 (Figure 
5A), suggesting that regulation of apoptosis via miR-138 and 
BIM is only partially involved in acquired TMZ resistance. 
In order to assess induction of apoptosis by a complementary 
approach, we checked for caspase 3 cleavage on protein 
level in LN-308 cells treated with TMZ, using staurosporin 
as a positive control. We failed to detect caspase 3 cleavage 
after a short period of TMZ treatment (1–2 days), as well as 
after an extended period of 4–8 days (Figure 5B). Next we 
investigated the protein levels of the pro-apoptotic protein 
BIM and of the anti-apoptotic Bcl-2 family members Bcl-2, 
Bcl-xL and Mcl-1 after TMZ treatment. Interestingly, protein 
levels of Bcl-2 and Mcl-1 increased as early as 1 day after 
TMZ treatment, and in the case of Bcl-2, the protein levels 
were further elevated at later time points (day 2–8). BIM 
levels, however, decreased dramatically already after one 
day of TMZ treatment and remained constantly down up to 
8 days after stimulation (Figure 5B), indicating an induction 
of a pro-survival signaling pathway mediated by the anti-
apoptotic protein stabilization as well as BIM degradation 
rather than apoptotic cell death.
Autophagy is induced by TMZ and miR-138, 
negatively correlates with BIM protein levels, 
and acts as a pro-survival pathway
Different pathways have been reported to promote 
survival or bypass cell death under stress conditions, 
including autophagy [26–29]. Accordingly, LN-308 were 
Figure 3: Overexpression of miR-138 confers TMZ and CCNU resistance in glioma cells. (A) LN-308 and ZH-305 cells 
were transfected with miR-138 mimics or control and TMZ or (B) CCNU sensitivity was assessed by clonogenic survival assays in LTC 
and spherogenicity assays in GIC (concentration of mimic/control: 50 nM for LTC, 100 nM for GIC) (*p < 0.05, **p < 0.01, ***p < 0.001, 
unpaired Student’s t-test).
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Figure 4: BIM downregulation via miR-138 confers TMZ resistance to glioma cells. (A) Immunoblot for BIM detection 
in LN-18, LN-229 and LN-308 parental versus resistant (R) cells (B) and in LN-308 or LN-229 cells transfected with miR-138 mimic, 
inhibitor or the respective control (100 nM); lysates were collected 72 h post-transfection. Quantification of protein bands was performed 
by densitometry, and the values stated under each band represent the normalized value to the corresponding loading control signal. 
(C) Luciferase reporter assay in LN-308 cells co-transfected with psiCheck2 empty vector, psiCheck2_Bim vector or one of the three 
mutant control vectors (psiCheck2_mut1, psiCheck2_mut2 and psiCheck2_mut3) and miR-138 mimic or control (transfection performed 
with 100 ng vector and 100 nM mimic/control concentration). Left panel: schematic of the two miR-138 binding sites in the 3′UTR 
region of the BIM mRNA, and the content of each vector construct (red cross represents mutation in the recognition site). Right panel: 
representative luciferase reporter assay. (D) siRNA-mediated silencing of BIM in LN-308 cells confirmed by immunoblot analysis (siRNA 
concentration: 100 nM). (E) Clonogenic survival assay after TMZ exposure of LN-308 cells transfected with two different siBim constructs 
(siBim1 and siBim2) or with siControl (siCtrl) (100 nM). (F) Clonogenic cell survival assay after TMZ treatment (37.5 μM) in combination 
with ABT-737 (3.3 μM) or DMSO of siBim1 or siControl transfected LN-308 cells. All values were normalized to siCtrl cells treated with 
DMSO (solvent control) and TMZ-untreated cells.
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exposed to TMZ and activation of autophagy was measured 
by conversion of the light chain 3-I (LC3-I) to LC3-II, a 
marker for autophagy [30]. Indeed, TMZ treatment led to a 
strong increase in LC3-II levels over time (Figure 5C). Since 
BIM protein levels are negatively regulated by miR-138, and 
miR-138 expression in turn is associated with TMZ-induced 
resistance, we assessed the correlation between miR-138-
dependent BIM regulation and autophagy in response to 
TMZ in glioma cells. Indeed, we recapitulated induction 
of autophagy in LN-308_R cells, where BIM levels were 
reduced (Figure 5C). More importantly, knockdown of 
BIM or transfection of miR-138 mimic led to enhanced 
autophagy as assessed by increased LC3-II production 
(Figure 5C). Band intensity quantification confirmed a 
reduction of BIM protein levels in the miR-138 mimic-
transfected cells. To assess whether the induced autophagy 
in LN-308 cells plays a chemoprotective role, we performed 
clonogenic survival assays with TMZ in the presence 
Figure 5: TMZ and miR-138 induce little apoptosis but cytoprotective autophagy. (A) Annexin V/PI flow cytometric analyses 
of LN-308 mim-138/control (left panel) or siBim/control (right panel) transfected cells treated with TMZ (100 µM) 1 and 3 days later. 
(B) Immunoblot analysis of cleaved caspase 3 (Casp-3) levels in LN-308 cells at different indicated time points after DMSO (vehicle 
control), TMZ (100 µM) or staurosporin (Stauro, 2 μM) stimulation (left panel), and of Bcl-2, Bcl-xL, Mcl-1 and BIM levels in LN-308 
cells at different indicated time points after DMSO (vehicle control), TMZ (100 μM) or staurosporin (Stauro, 2 μM) stimulation (middle 
panel, right panel). (C) Immunoblot analysis of LC3 A/B I and II levels in LN-308 cells at different indicated time points after DMSO 
(vehicle control), TMZ (100 μM) or staurosporin (Stauro, 2 μM) stimulation (left panel); immunoblot analysis of LC3 A/B I and II levels 
and BIM levels in LN-308 and LN-308_R cells; LN-308 cells were transfected with siCtrl or 4 different siBim molecules (100 nM), 
and mimic-ctrl (mim-ctrl) or mimic-138 (mim-138) molecules (50 nM), and cell lysates were collected 72 h after transfection (right 
panel). Quantification of protein bands was performed by densitometry for BIM levels in mim-ctrl and mim-138 transfected cells; values 
representing the normalized value to the corresponding loading control signal were 1.38 for mim-ctrl and 1.14 for mim-138, respectively 
(D) Clonogenic survival assay after TMZ exposure of LN-308 cells treated with the autophagy inhibitor 3-MA (2 mM) or solvent control.
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or absence of the autophagy inhibitor 3-methyl adenine 
(3-MA). When autophagy was blocked, cells were sensitized 
to TMZ (Figure 5D), suggesting that autophagy is a pro-
survival signal mediating TMZ resistance in glioma cells. 
DISCUSSION
Increasing evidence suggests that miRNAs play 
important roles in proliferation, invasion and migration 
as well as spontaneous and induced cell death in multiple 
cancer entities, including glioblastoma [31, 32]. Moreover, 
numerous studies have implicated altered miRNA 
expression in constitutive or acquired resistance to specific 
cancer treatments, such as irradiation or chemotherapy 
[33, 34]. Here we used microarray-based miRNA 
expression profiling of paired parental and TMZ-resistant 
glioma cell lines [14] to identify novel miRNA candidates 
potentially mediating resistance of glioma cells to TMZ, 
which together with radiotherapy constitutes the current 
standard of care in glioblastoma patients [3]. We provide 
evidence that miR-138 mediates acquired TMZ resistance 
in glioblastoma by regulating the apoptosis inducer BIM 
and autophagy. 
miR-138 has been implicated in the promotion of 
growth and survival of glioma stem cells [18], however, 
it appears to have an opposite role as a tumor suppressor 
in other cancers [16, 35]. Upregulation of miR-138 in 
recurrent glioblastomas of patients progressing after 
radiotherapy and TMZ confirmed the potential in vivo 
relevance of our in vitro profiling approach (Figure 1E). We 
found no clear-cut association between baseline miR-138 
expression levels and TMZ sensitivity of various glioma 
cell lines (Figure S1). This finding may partially be due to 
the overwhelming role of MGMT promoter methylation 
and expression in TMZ sensitivity [36], whose strong 
impact on alkylator resistance might override the effects 
of miR-138-mediated TMZ resistance in these cell lines. 
Moreover, miR-138 may be of particular importance 
in acquired rather than constitutive TMZ resistance, 
consistent with the observation that DNA damage induces 
expression of different microRNAs via transcriptional or 
post-transcriptional regulation [37]. 
We confirmed as previously described [18] that 
overexpression of miR-138 promotes cell cycle progression 
and drives glioma cell proliferation (Figure 2B–2D), but this 
is at odds with the report that miR-138 overexpression in 
glioma reduced cell proliferation in vitro and tumorigenicity 
in vivo through inducing a G1/S cell cycle arrest by inhibition 
of a EZH2-CDK4/6-pRb-E2F1 signaling loop [19].  
Consistent with our observation in primary tumors 
in vivo (Figure 1E), transfection of glioma cell lines or 
glioma stem-like cells with miR-138 mimics increased 
TMZ resistance (Figure 3A); yet, this effect was only 
seen in models with low baseline miR-138 expression. 
Consistently, there was cross-resistance to another 
alkylating drug, CCNU, but not to irradiation or other 
chemotherapeutic agents such as vincristine or etoposide, 
confirming a specific role of this miRNA in the resistance 
pathway to alkylator-induced DNA damage (Figure 3B; 
Figure S2B). One challenge that we faced while studying 
the role of miR-138 was that miR-138 depletion by an 
inhibitor approach did not show the opposite effect of 
miR-138 over-expression by adding mimic (Figure S3). 
We may have encountered this problem due to a technical 
limitation of the used miRNA silencing approach: 
miRNA inhibitors are designed as microRNA antisense 
oligonucleotides, which are supposed to saturate 
endogenous levels of miRNA by binding them, thus 
preventing the binding to the target mRNA molecules. 
However, if the number of antisense oligonucleotides 
is not in several-fold excess of the miRNA copies per 
cell, the miRNA saturation is not complete, hence the 
residual levels that we observe upon miR-138 silencing 
(Figure S3A) might be sufficient to maintain the original 
phenotype [38, 39]. We also investigated potential 
mechanisms that could underlie the induction of TMZ 
resistance by miR-138. For this purpose, we studied two 
predicted miR-138 targets for their involvement in TMZ 
resistance of glioma cells, namely CD166/ALCAM and 
BCL2L11/BIM.  Expression of ALCAM on glioma stem 
cells has been previously linked to the regulation of 
glioblastoma invasion [40]. Moreover, RNAi-mediated 
silencing of ALCAM induced chemotherapy resistance 
in pancreatic cancer cells [41]. However, while we found 
decreased ALCAM expression levels in TMZ-resistant 
cells, our functional analyses did not confirm an effect 
of ALCAM downregulation on glioma cell sensitivity 
to TMZ (Figure S4D). In contrast, BIM, a pro-apoptotic 
BH3-only protein of the Bcl-2 family emerged as an 
interesting target to study. We succeeded to confirm the 
in silico predictions that BIM is a direct target of miR-138 
by luciferase reporter assays (Figure 4C). We further 
show that transient knockdown of BIM increased TMZ 
resistance of glioma cells (Figure 4E), thus mimicking 
the miR-138 over-expression phenotype. Therefore, 
we postulate that the resistance phenotype mediated by 
miR-138 is partly dependent on BIM downregulation. 
Two other microRNAs, miR-17 and miR-20a, have been 
previously shown to target BIM, and their suppression 
sensitized chemoresistant leukemia cells to DNA damage-
induced apoptosis [42]. MiR-148a has also been shown to 
target BIM in glioma stem cells and thereby control cell 
proliferation and apoptosis [43]. However, the contribution 
of miR-mediated BIM regulation to the response of glioma 
cells to TMZ has not been addressed before. We observed 
that BIM silencing led to increased TMZ resistance, which 
was reversed by adding sub-lethal concentrations of the 
BH3-mimetic ABT-737 (Figure 4F). All experiments 
assessing TMZ resistance employed clonogenic survival 
assays, which measure the potential of single cells to form 
colonies over long periods of time (up to 20 days) upon 
different stimulations. Since BIM regulated resistance to 
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TMZ, we measured TMZ-induced apoptosis by AnnexinV/
PI (AV/PI) assay and detection of cleaved caspase 3. Our 
flow cytometry AV/PI measurements (Figure 5A) revealed 
a minor induction of apoptosis 72h after TMZ treatment 
(up to 10%) as described before [27, 44]. However, these 
studies did not investigate caspase 3 cleavage after TMZ 
exposure of glioma cells, but only after alkylating MNNG 
treatment, reporting cleavage at 96 h post treatment. Yet, 
LN-308 cells stimulated with TMZ did not exhibit caspase 
3 cleavage at early or later time-points (Figure 5B). 
Literature reports suggest that TMZ can induce autophagy 
or senescence rather than apoptosis [27, 45–47]. These 
studies offer conflicting conclusions whether autophagy 
is a pro- or anti-survival mechanism. Indeed, autophagy 
as a mechanism for maintenance of cellular homeostasis 
can have tumor-suppressive properties in healthy cells. 
In neoplastic cells, however, autophagic responses 
rather protect from intracellular and environmental 
stress, thus promoting tumor progression and resistance 
to therapy [29]. We indeed saw induction of autophagy 
after TMZ treatment at day 1 up to day 8 (Figure 5C). 
This consequence of TMZ exposure was accompanied by 
reduction of the pro-apoptotic protein BIM and increase 
of anti-apoptotic Bcl-2 family proteins (Figure 5B). 
Interestingly, BIM has previously been described to 
inhibit autophagy by binding and mislocalizing Beclin 1, 
an autophagy regulator [48]. Additionally, increased 
autophagy was seen in TMZ-resistant cells, and upon 
miR- 138 over-expression or BIM silencing to a lesser extent 
(Figure 5C). Finally, blocking autophagy by the inhibitor 
3-MA led to increased TMZ sensitivity (Figure 5D). 
It is tempting to speculate that TMZ treatment, leading 
to increased miR-138 expression, which in turn reduces 
BIM levels, leads to autophagy that results in cell survival, 
thus TMZ resistance. However, probably additional TMZ-
induced mechanisms further regulate autophagy (Figure 6). 
Figure 6: Autophagy mediates TMZ resistance via the miR-138/BIM axis. Long-term TMZ treatment induces miR-138 
expression, which in turn suppresses BIM translation. Hence, BIM-mediated autophagy inhibition is blocked, and increased autophagy 
promotes cell survival of the glioma cells.
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In conclusion, we demonstrate a role for miR-138 
in acquired TMZ resistance in glioma cells. Moreover, 
we establish a functional link between miR-138-mediated 
resistance and BIM, and confirm that down-regulation of 
BIM by miR-138 promotes TMZ resistance. Additionally, 
we propose that the miR-138/BIM axis mediates resistance 
to TMZ by autophagy. Hence, its targeting may represent 
a novel strategy to overcome acquired TMZ resistance in 
glioblastoma.
MATERIALS AND METHODS
Cells and reagents
The human long-term glioma cell lines (LTC) LN-18, 
LN-229, LN-308, LN-319, LN-428, D247MG, A172, 
U87MG and T98G were kindly provided by Dr. N. 
de Tribolet (Lausanne, Switzerland). TMZR sublines 
(LN-18_R, LN-229_R and LN-308_R) have been 
characterized [14]. The following glioma-initiating cells 
(GIC) grown as sphere cultures were used: ZH-161, ZH-305, 
T-325, T-269 and S-24 [49]. Stock solutions of TMZ 
(Schering-Plough, Kenilworth, NJ) and lomustine (CCNU) 
(Dr. Reddy’s Laboratories Ltd., Hyderabad, India) at 100 mM 
were prepared in dimethylsulfoxide (DMSO); aliquots were 
stored at −20°C. Etoposide (Sigma-Aldrich, St. Louis, MO) 
stock solution was prepared in DMSO at 50 mM, ABT-737 
(ChemieTek, Indianapolis, IN) was prepared as 50 mM 
stock solution in DMSO. Vincristine was purchased 
from Tocris Bioscience (Bristol, UK) and prepared as 
48 mM stock solution in DMSO. 3-methyl adenine 
(3-MA) (Sigma solutions) were freshly prepared in water 
at 100 mM. Irradiation experiments were performed by 
irradiation of the cells in a Co-radiation source (Gebrüder 
Sulzer, Thermische Energiesysteme, 60-Co, Winterthur, 
Switzerland).
MiRNA and mRNA extraction from glioblastoma 
tissue samples and glioma cells
Deep-frozen tissue samples from primary and 
recurrent glioblastomas of 10 patients treated with TMZ/
RT→TMZ after surgery were selected from the tumor 
tissue bank of the Department of Neuropathology, Heinrich 
Heine University, Düsseldorf, Germany, and investigated as 
approved by the institutional review board (study number 
3825). Tissue samples were snap frozen immediately after 
resection and stored at -80 °C. Each tissue specimen was 
histologically evaluated for sufficient tumor cell content. 
miRNA was extracted from frozen tissue samples or cell 
Qiagen, Hilden, Germany). Total RNA was prepared using 
the NucleoSpin System (Macherey-Nagel AG, Oensingen 
SO, Switzerland). RNA quantity was determined with the 
NanoDrop ND-1000 spectrophotometer (PeqLab, Erlangen, 
Germany). miRNA and mRNA quality assessment 
was done with an Agilent 2100 bioanalyzer (Agilent 
Technologies, Santa Clara, CA). Only RNAs with a RNA 
integrity number of ≥ 7 were used for molecular analyses. 
Microarray-based miRNA and mRNA 
expression profiling 
For microarray-based miRNA expression analysis 
400 ng of high-molecular weight RNA was biotin-
labelled using the Affymetrix® FlashTag™ Biotin HSR 
RNA Labeling Kit (Affymetrix, Santa Clara, CA) and 
hybridized to GeneChip® miRNA 2.0 arrays (Affymetrix). 
Transcriptome-wide changes in gene expression were 
determined by hybridization to Gene Chip® Human 
Genome U133 Plus 2.0 arrays (Affymetrix) [50]. Sample 
preparation for mRNA expression analysis was done with 
2.5 µg of total RNA using the One Cycle Target Labelling 
and Controls kit (Affychip hybridizations were performed 
at the Center for Biological and Medical Research (BMFZ) 
at Heinrich Heine University Düsseldorf using a GeneChip 
Hybridization Oven 645 and a GeneChip® Scanner 3000 7G. 
Three independent batches from each parental and TMZR 
cell line were subjected to the Affymetrix chip analyses. 
Bioinformatic and statistical analyses of 
microarray data 
All steps of the microarray analysis pipeline were 
set up within the R framework for statistical computing 
[51]. The microarray dataset was normalized and log2-
transformed using the robust multi-array average (RMA) 
method implemented in the affy package [52]. Differential 
expression of miRNA was assessed by computing the 
moderated t-statistics using the LIMMA package [53]. 
The resulting p-values were corrected for multiple testing 
by controlling the false discovery rate [54]. A miRNA was 
considered to be differentially expressed if the corrected 
p-value was below 0.05. For in silico predictions of 
potential miRNA targets, the miRWalk online database on 
predicted and validated miRNA targets was used [21].
Transfection reagents, miRNA mimics and 
inhibitors, and siRNA molecules
The miRIDIAN miR-138 mimics and miR-138 
miRIDIAN hairpin inhibitors and respective control molecules 
were purchased from Dharmacon (Dharmacon GE Healthcare, 
Lafayette, CO). For ALCAM knockdown ON-TARGET plus 
siRNA-SMART pool (L-004574) was used (Dharmacon). 
BIM gene silencing was performed using FlexiTube siRNA 
(siBim1- SI02655359, siBim2 – SI03056466, siBim3 – 
SI03062080, siBim4 – SI04951961; Qiagen, Hilden, Germany). 
Transient transfection of glioma cells with mimics, inhibitors 
or siRNA was performed using Lipofectamine RNAiMAX 
(Life Technologies, Carlsbad, CA, USA). Lipofectamine 2000 
was used for co-transfection of luciferase reporter vector and 
miRNA mimics or inhibitor molecules (Life Technologies).
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Transient transfection
LTC were seeded in six-well plates at 250,000 to 
600,000 cells/well. Cells were transfected with specific 
miRNA mimics, miRNA inhibitors, siRNA, or respective 
control molecules 24 h later. For clonogenic assays and 
mRNA or miRNA expression analyses, cells were harvested 
24 h post transfection, while for preparation of protein 
lysates, medium was changed 24 h post transfection and the 
cells were harvested 48 h later.
GICs were dissociated using Accutase cell detachment 
solution (PAA Laboratories; Pasching, Austria). Two million 
cells were transfected using the Neon Transfection System 
electroporation device and kit (Invitrogen, Life Technologies) 
with 100 nM mimic, inhibitor, siRNA, or control. After 
transfection, cells were seeded in 6-well plates in neurobasal 
conditions for recovery. One day later cells were processed 
for clonogenic survival assay, mRNA or microRNA isolation, 
or 72 h later for protein lysate preparation. 
Quantitative reverse transcriptase PCR
Complementary DNA transcription from miR-138 
and RNU48 and subsequent real-time PCR-FAM detection 
was performed using specific TaqManTM MicroRNA 
Assays (hsa-miR-138 assay ID: #002284; RNU48 assay 
ID: #001006) (Applied Biosystems, Life Technologies). 
For mRNA expression analyses, total RNA was transcribed 
into cDNA using the iScript cDNA Synthesis Kit (Bio-
Rad Laboratories; Hercules, CA). cDNA amplification 
was monitored using SYBRGreen chemistry on the 
7300 Real time PCR System (Applied Biosystems). 
Conditions for PCR reactions were: 40 cycles, 95°C/15 sec, 
60°C/1 min, using the following specific primers: 
GAPDH fwd: 5′-CTCTCTGCTCCTCCTGTTCGAC-3′ 
(NM_002046, 114-135 nt), GAPDH rv: 
5′-TGAGCGATGTGGCTCGGCT-3′ (NM_002046, 182-
164 nt), ALCAM fwd: 5′-TTCTTAGCACCTGGCGTTTC-3′ 
(NM_001627, 293-312 nt), ALCAM rv: 
5′-CGGTTCTTTTCGCTGGTATC-3′ (NM_001627, 388-
369 nt), BIM fwd: 5′-TTGATTCTTGCAGCCACCCT-3′ 
(NM_138621, 120-139 nt), BIM rv: 
5′-GAACGCAGCGAACCGAATAC-3′ (NM_138621, 
193-174 nt). Data analysis was done using the ΔCT method 
for relative quantification, GAPDH and RNU48 were used as 
control genes for mRNA or miRNA expression [55]. 
miRNA expression analyses in glioma tissue 
specimens
Reverse transcription of mature miR-138 in primary 
and recurrent glioblastomas was carried out with 100 ng 
of total RNA as template using stem-loop primers specific 
for miR-138 and Superscript® II reverse transcriptase (Life 
Technologies). Real-time PCR on the StepOnePlus™ system 
(Life Technologies) was done with TaqMan® miRNA assays 
(Applied Biosystems, Life Technologies) for miR-138 
(Assay ID: #002284) and U6 snRNA (Assay ID: #001973) 
as reference. Expression changes relative to a calibrator 
sample (Universal Human Reference RNA, Stratagene, La 
Jolla, CA) were calculated with the 2−∆∆Ct method [56]. 
Immunoblotting 
Immunoblot analysis was performed as described 
previously [57]. The following primary antibodies were 
used: anti-β-actin (csc-1616) (Santa Cruz Biotechnology, 
Dallas, TX), anti-SOX4 antibody (ab41891) (Abcam, 
Cambridge, UK), anti-ALCAM antibody (MAB656) (R & D 
Systems, Minneapolis, MN) anti-Cleaved Caspase-3 
(Asp175) (#9661), anti-Bcl-xL (#2764) and anti-LC3 A/B 
(#4108) (Cell Signaling Technology, Danvers, MA), and 
anti-BIM antibody (B7929) (Sigma-Aldrich).
Proliferation, viability, clonogenicity and flow 
cytometry
BrdU cell proliferation assays were performed using a 
Cell Signaling Technology kit (Danvers, MA). Briefly, 24 h 
after miRNA mimic or control transfection, the cells 
were seeded at 5,000 cells/well in 96-well plates. 
BrdU reagent was added 24 h later in serum-free 
DMEM medium, and cells were grown for another 
24 h. BrdU detection was performed according to 
the user’s manual. Trypan blue dye exclusion assay 
was also used to monitor cell viability. Transfected 
cells were seeded at a density of 5,000 cells/well 
in 12-well plates. Medium was changed to serum-free 
DMEM 24 h later for specified experiments; after 24 h 
floating and attached cells were harvested, and living and 
dead cells were counted in a Neubauer chamber using 
0.4% trypan blue. Clonogenic assays for adherent LTC 
and GIC cultures were performed as described previously 
[14, 50]. For cell cycle and cell death analysis, transfected 
LN-308 cells were treated as indicated, harvested at the 
indicated time points after transfection (cell cycle analysis) 
or post-treatment (cell death analysis) and analyzed [14]. 
3′UTR luciferase gene reporter assay
A 1281-bp fragment of the BIM 3′UTR 
sequence containing two predicted binding sites for 
miR- 138 was subcloned into the psiCHECK™-2 dual 
luciferase vector (Promega, Madison, WI). For this 
purpose cDNA from LN-308 cells was used and the 
following primers for amplification of the insert: fwd: 
5′-CTCGAGATTATGCAGCCAGCGGTTCT-3′, rev: 
5′-GCGGCCGCAGCAGGCACAGAGAAAGAGC-3′. 
Restriction enzymes used for cloning the insert 3′ to the 
Renilla luciferase were XhoI and NotI (New England 
Biolabs, Ipswich, MA). For the control vectors the same 
fragment of BIM 3′UTR sequence was synthesized de novo, 
bearing mutations in the two miR-138 recognition sites: 
psiCheck2_mut1 (mutations in site 161-185 nt); psiCheck2_
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mut2 (mutations in site 1223-1249 nt); psiCheck2_mut3 
(mutations in both recognition sites) (Eurofins Genomics, 
Ebersberg, Germany). Dual luciferase reporter assays 
were performed seeding 20,000 LN-308 cells per well in a 
96-well plate. Following attachment overnight, cells were co-
transfected with 100 ng of the respective reporter construct 
and 50 nM of miR-138 mimic or control molecules. After 
48 h, cells were lysed, luciferase activity was measured, and 
Renilla values normalized to Firefly luciferase.
The cancer genome atlas (TCGA) database
Data was obtained from the glioblastoma data set of 
the Cancer Genome Atlas network (http://cancergenome.
nih.gov/) [22]. The affymetrix probesets used in the TCGA 
database were 201952_at for ALCAM and 208536_s_at 
for BCL2L11. Survival analysis within the glioblastoma 
data set of the TCGA database was performed using the 
Kaplan-Meier analysis module of the R2 microarray 
analysis and visualization platform (http://r2.amc.nl).
Statistical analyses
Data are expressed as means and standard deviations. 
The experiments shown were independently repeated a 
minimum of three times with similar results. If not otherwise 
indicated, results of representative experiments are shown. 
Significance was assessed using two-sided unpaired 
Student’s t-test, paired Student´s t-test for comparison of 
miR-138 expression in primary and recurrent glioblastomas, 
one-sample Student’s t-test for analysis of luciferase reporter 
results or two-way ANOVA with post hoc Bonferroni test, 
and correlation was calculated by assessing the Spearman’s 
coefficient (r) (GraphPad Prism 5, La Jolla, CA) (*p < 0.05, 
**p < 0.01, ***p < 0.001).
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